Home » Stocks » Assertio Therapeutics

Assertio Therapeutics, Inc. (ASRT)

Stock Price: $0.900 USD 0.030 (3.45%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
After-hours: $0.910 +0.010 (1.11%) Aug 4, 7:24 PM

Stock Price Chart

Key Info

Market Cap 94.77M
Revenue (ttm) 194.13M
Net Income (ttm) -161.67M
Shares Out 105.36M
EPS (ttm) -2.23
PE Ratio n/a
Forward PE 1.53
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $0.900
Previous Close $0.870
Change ($) 0.030
Change (%) 3.45%
Day's Open 0.860
Day's Range 0.858 - 0.940
Day's Volume 665,456
52-Week Range 0.550 - 3.500

More Stats

Market Cap 94.77M
Enterprise Value 46.66M
Earnings Date (est) Aug 7, 2020
Ex-Dividend Date n/a
Shares Outstanding 105.36M
Float 61.33M
EPS (basic) -2.29
EPS (diluted) -2.23
FCF / Share 0.52
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 38.77%
Payout Ratio n/a
Shares Short 1.72M
Short Ratio 1.17
Short % of Float 1.48%
Beta 2.20
PE Ratio n/a
Forward PE 1.53
P/FCF Ratio 2.58
PS Ratio 0.49
PB Ratio 1.21
Revenue 194.13M
Operating Income -214.13M
Net Income -161.67M
Free Cash Flow 36.74M
Net Cash 48.11M
Net Cash / Share 0.46
Gross Margin 113.34%
Operating Margin -110.30%
Profit Margin -84.00%
FCF Margin 18.93%
ROA -2.61%
ROE -110.51%
ROIC -48.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$2.42*
(168.89% upside)
Low
1.35
Current: $0.900
High
3.50
Target: 2.42
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue23031238145634339013490.8213380.76
Revenue Growth-26.39%-18.11%-16.49%33.02%-12.2%190.87%47.78%-31.7%64.64%-
Gross Profit22029330836827537512784.7812772.67
Operating Income-19443.66-42.1824.51-50.402379.32-30.3570.703.63
Net Income-21736.91-102-88.72-75.7413243.31-29.7870.733.90
Shares Outstanding70.7263.7962.7061.3060.1258.2956.7455.8954.5652.53
Earnings Per Share-3.070.57-1.63-1.45-1.262.050.75-0.531.260.07
EPS Growth-----173.33%--1700%-
Operating Cash Flow90.4872.5062.1771.26152-55.929.75-30.9957.65-2.38
Capital Expenditures-1.48-5.36-0.39-2.86-1.72-0.60-1.81-6.88-0.70-0.18
Free Cash Flow88.9967.1461.7868.40151-56.527.94-37.8756.95-2.56
Cash & Equivalents42.1111112817721055927266.8186.1570.35
Total Debt351566627719800230---2.17
Net Cash / Debt-309-455-499-541-59133027266.8186.1568.18
Assets5279331,0391,2251,35771150914216487.03
Liabilities4697138699751,04234737157.7258.4563.93
Book Value57.9622017025131536413783.9410623.11
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Assertio Therapeutics, Inc.
Country United States
Employees 125
CEO Todd N. Smith

Stock Information

Ticker Symbol ASRT
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: ASRT
IPO Date November 5, 1997

Description

Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in neurology, orphan, and specialty areas in the United States. The company offers Gralise (gabapentin), a once daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; and Zipsor (diclofenac potassium liquid filled capsules), a non-steroidal anti-inflammatory drug for treating mild to moderate acute pain. It also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to require daily, around-the-clock, and long term opioid treatment, including neuropathic pain related to diabetic peripheral neuropathy in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, the company offers long-acting cosyntropin, an alcohol-free formulation of synthetic adrenocorticotropic hormone. Assertio Therapeutics, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.